Lonza Group AG highlights its role in global biopharmaceutical manufacturing. The company continues to invest in contract development and manufacturing capabilities
06.07.2026 - 10:49:17 | ad-hoc-news.de
Lonza Group AG is a leading global partner to the pharmaceutical, biotech and nutrition industries, supplying contract development and manufacturing services for a wide range of therapies and ingredients.
The company, listed in Switzerland under ISIN CH0013841017, plays an important role in the global biopharmaceutical supply chain by supporting customers across early-stage development, clinical manufacturing and commercial-scale production.
Broad role in biopharmaceutical manufacturing
Lonza Group AG operates a diversified business model focused on contract development and manufacturing services for biologics, small molecules and cell and gene therapies, alongside specialty ingredients used in health, nutrition and consumer care.
Its operations include development laboratories, clinical-scale plants and large commercial manufacturing sites that support pharmaceutical and biotechnology customers worldwide, helping them to bring new therapies from research to market.
Focus on complex therapies and outsourcing trends
Over recent years, the company has increasingly concentrated on complex biologics, antibody-drug conjugates and cell and gene therapies, reflecting broader industry trends toward outsourcing and the growing demand for specialized manufacturing capacity.
Analysts note that large pharmaceutical companies as well as emerging biotechs continue to rely on external partners for flexible capacity, technical expertise and regulatory support, and Lonza Group AG is one of the established providers in this space.
Further information on Lonza Group AG
Company filings and investor presentations provide additional detail on segment performance, capital expenditure plans and long-term strategy.
Representative product and services
A representative part of Lonza Group AG's business is its contract development and manufacturing services for monoclonal antibodies and other biologic medicines, which include upstream cell culture, downstream purification and fill-and-finish operations under strict quality and regulatory standards.
Stock and listing information
Lonza Group AG is listed on the SIX Swiss Exchange, giving international investors access to a major European contract development and manufacturing organization focused on biopharmaceuticals and specialty ingredients.
Lonza Group AG at a glance
- Company: Lonza Group AG
- ISIN: CH0013841017
- Ticker: LONN
- Exchange: SIX Swiss Exchange
- Price (as of latest close): data not specified
- Market cap: data not specified
- Sector / Industry: Health care - life sciences tools and services
- Index membership: data not specified
- Next earnings date: not yet officially scheduled
This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.
